NMC
ATNM icon

Nine Masts Capital’s Actinium Pharmaceuticals ATNM Stock Holding History

Nine Masts Capital’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-35,227
Closed -$35.1K – 179
2026
Q1 		$35.1K Buy
35,227
+22,287
+172% +$26.5K 0.01% 201
2025
Q4 		$17.6K Buy
+12,940
New +$18.9K ﹤0.01% 115

Other funds holding ATNM

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Compass Financial Management Tampa, Florida $829M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Nine Masts Capital's ATNM Position: Q2 2026 in Review

Nine Masts Capital sold out of Actinium Pharmaceuticals (ATNM) in Q2 2026, closing a stake of 35,227 shares — an estimated $35.1K sold.

Nine Masts Capital first reported a position in ATNM in Q4 2025 and held it in 2 quarters. The position peaked at $35.1K in Q1 2026. 47 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

  • Nine Masts Capital reported no remaining Actinium Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Nine Masts Capital sold 35,227 Actinium Pharmaceuticals shares in Q2 2026, an estimated $35.1K.
  • Nine Masts Capital first reported a position in Actinium Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Nine Masts Capital's Actinium Pharmaceuticals position peaked at $35.1K in Q1 2026.
  • 47 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.